Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TOVX |
---|---|---|
09:32 ET | 487 | 0.477 |
10:08 ET | 2558 | 0.470001 |
10:19 ET | 1239 | 0.48 |
10:30 ET | 100 | 0.48 |
10:37 ET | 3000 | 0.4801 |
10:39 ET | 480 | 0.480001 |
11:24 ET | 5100 | 0.471 |
11:44 ET | 650 | 0.485 |
12:05 ET | 725 | 0.4885 |
12:14 ET | 200 | 0.4702 |
12:27 ET | 100 | 0.4801 |
12:36 ET | 104 | 0.489999 |
12:38 ET | 1599 | 0.475 |
12:59 ET | 181 | 0.4775 |
01:12 ET | 650 | 0.4776 |
01:46 ET | 100 | 0.49 |
01:57 ET | 108 | 0.4821 |
02:47 ET | 254 | 0.49 |
02:49 ET | 1000 | 0.489999 |
03:07 ET | 1000 | 0.475 |
03:09 ET | 200 | 0.4801 |
03:41 ET | 13178 | 0.445 |
03:43 ET | 4960 | 0.4724 |
03:52 ET | 100 | 0.4724 |
03:56 ET | 200 | 0.47 |
03:57 ET | 500 | 0.4695 |
03:59 ET | 100 | 0.469 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Theriva Biologics Inc | 8.0M | -0.4x | --- |
Protagenic Therapeutics Inc | 7.8M | -1.9x | --- |
Galera Therapeutics Inc | 7.6M | -0.1x | --- |
Lixte Biotechnology Holdings Inc | 7.6M | -1.2x | --- |
Tenax Therapeutics Inc | 7.5M | 0.0x | --- |
Cyclerion Therapeutics Inc | 8.7M | -0.6x | --- |
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patients immune system. The Company’s lead candidates are: VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier; SYN-004 (ribaxamase) which is designed to degrade used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 17.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.45 |
EPS | $-1.18 |
Book Value | $3.61 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.